ClinicalTrials.gg
Sign In

Meningitis, Meningococcal clinical trials

The registry lists 125 studies for Meningitis, Meningococcal across more than 10 countries. 10 are recruiting or about to start. 111 of them are mainly about Meningitis, Meningococcal (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-21.

Get an email when these change. Save the Meningitis, Meningococcal studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
97
Status unknown
9
Recruiting
5
Not yet recruiting
5
Active, not recruiting
5
Terminated
3

Phase

Phase 3
54
Phase 2
35
Phase 4
16
Phase 1
13

Where

United States
36
China
19
Germany
11
Spain
10
United Kingdom
9
Italy
8

Who runs them

Novartis Vaccines (27) · Sanofi Pasteur, a Sanofi Company (22) · GlaxoSmithKline (9) · CanSino Biologics Inc. (8) · Pfizer (7) · Novartis (5) · Sinovac Biotech Co., Ltd (4) · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (4)

What is being tested here

Drugs under test in Meningitis, Meningococcal studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
4CMenB vaccine1411
Ciprofloxacin002
MenACWY001
Measles-Mumps-Rubella Vaccine011
13-valent pneumococcal vaccine011
Adacel001
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18001
Tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine011
MenB-FHbp vaccine001
Human papillomavirus vaccine, L1 type 16, 18011

Coming up

5phase 3 studies under way
6studies finish main data collection within a year4 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 6, phase 3 first

Who these studies take

Of the 5 Meningitis, Meningococcal studies recruiting now, 0 (0%) set no upper age limit and 5 (100%) stop at 75 or younger. 4 (80%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 5 (100%) take healthy volunteers.

Recruiting studies that take each age, of 5
AgeWomenMen
100 (0%)0 (0%)
181 (20%)1 (20%)
301 (20%)1 (20%)
401 (20%)1 (20%)
501 (20%)1 (20%)
650 (0%)0 (0%)
750 (0%)0 (0%)
850 (0%)0 (0%)

Across all 125 studies, recruiting or not: 91% stop at 75 or younger and 91% at 65; 77% take children; 1% are for women only and 0% for men only; 93% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Meningitis, Meningococcal studies take

Of 25 phase 3 interventional studies under Meningitis, Meningococcal, half reached primary completion within 7 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 37 mo6–20 · 25 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Newly registered1

Studies

Recruiting first, then most recently updated. Showing 50 of 125. Browse all 125 → or search them.